Project Grant R01CA279357
Award Date
7/3/24
Completion Date
6/30/29
Dollars Obligated
$639K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Hershey, PA 17033, USA
Similar Awards
The National Cancer Institute awarded a 3-year, $249,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to conduct research on decoding the genetic and epigenetic drivers of glioma tumor evolution and progression. The key objectives are to: 1) define how somatic mutations and epigenetic changes in glioma cells dysregulate transcriptional patterns and dictate...
This federal Project Grant award, valued at $201,172 and provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), aims to support research on cell-free DNA methylation patterns as a biomarker for tumor biology and clinical outcomes in glioblastoma patients. The primary goal is to develop a non-invasive method for longitudinal molecular profiling of glioblastoma, a lethal brain tumor, to improve risk stratification, clinical trial design,...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $678,228 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop GLISCAN, a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The project aims to optimize, verify, and validate the GLISCAN assay, which quantifies tumor mutations (TERT C228T/C250T, EGFRVIII, IDH1.R132H) and a...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $997,410 to Arizona State University to develop MRI-based techniques for detecting and differentiating invasive subtypes of high-grade glioma brain tumors. The goal is to leverage advanced diffusion MRI and deuterium-based metabolic MRI methods to spatially characterize the infiltrating "neuronal" and "glycolytic/plurimetabolic" glioma subtypes, which...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Medical College of Wisconsin, Inc. (MCW) aims to externally validate and integrate radio-pathomic models for identifying microscopic tumor infiltration and pathological heterogeneity in glioma patients. The $677,998 award will fund a 5-year research project with the following key objectives: Externally validate the performance of radio-pathomic maps in identifying measures...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to understand the metabolic mechanisms driving the progression of glioma, a highly lethal and treatment-resistant form of brain cancer. The $682,596 award to the University of Texas Southwestern Medical Center, with a sub-award to the University of Pittsburgh, will fund a 5-year research project to investigate the role of aberrant metabolite secretion in glioma-neuron...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop and evaluate a novel combinatorial therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products and services to be delivered under this 5-year award include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high...
The National Cancer Institute (NCI) awarded a $170,655 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University. This 2-year grant, effective July 1, 2025, aims to develop a new molecular method for mapping protein trafficking between glioblastoma (GBM) cells and other brain cell populations in an in vivo setting. The key products and services to be delivered under this grant include: Developing an esterase-activated bioorthogonal reaction...
This $686,979 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of California, San Francisco (UCSF) to investigate metabolic mechanisms of immunosuppression in diffuse midline gliomas (DMGs), a deadly form of childhood brain cancer. The key objectives are to: 1) delineate how the H3K27M genetic mutation in DMGs dysregulates citrate metabolism to drive tumor growth and immune evasion; 2) demonstrate that...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $677,801 to Yale University from January 2, 2025 to December 31, 2029 to develop and validate a novel magnetic resonance imaging (MRI) method called Deuterium Metabolic Imaging (DMI) for characterizing brain tumors, specifically glioblastoma (GBM), based on their altered glucose metabolism. The key products and services to be delivered...